CM 24

Drug Profile

CM 24

Alternative Names: CM24; MK 6018

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator cCAM Biotherapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD66 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 Mar 2017 Merck Sharp & Dohme terminates a phase I trial in Solid tumours (Combination therapy, Monotherapy, Recurrent, Late-stage disease) in USA and Israel (NCT02346955)
  • 03 Jun 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 01 Feb 2015 Phase-I clinical trials in Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Recurrent) in USA (IV) after February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top